The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme

• Autores: Omer Fat?h Olmez, Erdem Cubukcu, Turkkan Evrensel, M. Kurt, N. Avci, S. Tolunay, A. Bekar, A. Deligonul, M. Hartavi, N. Alkis, Osman Manavoglu
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 16, Nº. 2, 2014, págs. 173-177
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background and aims Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols.

    Methods Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 ± 12.9 years, age range: 23�81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures.

    Results Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 ± 2.3 vs. 22.6 ± 2.5 months, respectively, p < 0.01) and PFS (12.3 ± 2.1 vs. 19.1 ± 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2�1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1�2.3, p < 0.05).

    Conclusions Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care.